Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pasithea Therapeutics Corp. - Common Stock (NQ:KTTA)

0.7322 -0.0156 (-2.09%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pasithea Therapeutics Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics
From CAMAC PARTNERS, LLC AND AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD. AND LEONITE CAPITAL LLC
Via Business Wire
Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics
From CAMAC PARTNERS, LLC AND AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD. AND LEONITE CAPITAL LLC
Via Business Wire
Pasithea' Largest Investor Group Says AlloMek Therapeutics Deal Ill-timed, Highly Dilutive
Via Benzinga
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
Learn More about Pasithea Therapeutics by gaining access to the latest research report 
Via TheNewswire.com
A New BioTech Research Race Is Focused On Improving Life For MS Patients
When the world is focused on a global pandemic no one saw coming four years ago, the attention given to escalating diseases with no known cure can be hidden from the public consciousness. This is... 
Via Benzinga
Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics
From Camac Partners, LLC and Affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
EXCLUSIVE: Pasithea Bolsters CNS-Focused Pipeline With AlloMek Therapeutics Acquisition
Pasithea Therapeutics Corp (NASDAQ: KTTA) has acquired AlloMek Therapeutics LLC, a privately-held biotechnology company,  
Via Benzinga
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide... 
Via FinancialNewsMedia
New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope
People suffering from incurable neurological diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) hope new therapies and drugs will arrive sooner than later.    
Via Benzinga
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
By Mark Gilman, Benzinga 
Via News Direct
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
Vaccines that boost the body’s immune system against foreign proteins are different than those that are an inverse vaccine fighting an autoimmune disease. 
Via Benzinga
Ron Bauer, Author of Exit Plan: How to Raise Money & Go Public, has a book release planned for December 2022
Via Get News
Investor Group Sends Letter to Pasithea Therapeutics’ Board of Directors
From Camac Partners, LLC and Affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC
Via Business Wire
Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics
From Camac Partners, LLC, Affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting
From CAMAC PARTNERS, LLC, AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD., AND LEONITE CAPITAL LLC
Via Business Wire
EXCLUSIVE: Pasithea's Multiple Sclerosis Vaccine Candidate Shows Efficacy In Animal Studies, With Potential In Monkeypox
Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced results from a preliminary preclinical proof of concept study of PAS002, its tolerizing vaccine for multiple sclerosis (MS). 
Via Benzinga
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by... 
Via FinancialNewsMedia
Smaller Biotechs May Pave Way For New Generation Of Therapeutics For Hard-to-Treat Neurological Disorders
An estimated 200 million Americans — more than 60% of the population — suffer from at least one neurological disorder. That includes dementia, strokes, migraines and other diseases or infections that... 
Via Benzinga
Investor Group Urges Stockholders of Pasithea Therapeutics Corp. to Call Special Meeting
From CAMAC PARTNERS, LLC, AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD., AND LEONITE CAPITAL LLC.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Applied DNA Sciences (NASDAQ:APDN) stock rose 90.0% to $5.32 during Tuesday's after-market session. At the close, Applied DNA Sciences's trading volume reached 28.8 million shares. This is... 
Via Benzinga
A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea
Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotech company looking for new treatments for psychiatric and neurological disorders, received an AU$1 million (US$694,000) gran 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million. 
Via Benzinga
Pasithea's Latest Drug Candidate Could Bring New Hope To ALS Patients Without Effective Treatment Options
Amyotrophic lateral sclerosis (ALS) is a rare but painful and fatal disease that slowly shuts down all voluntary movements in the body, from walking to breathing. 
Via Benzinga
Pasithea Therapeutics Receives AUD $1 Million Research Award Following Recent Acquisition
Pasithea Therapeutics Corp. (NASDAQ: KTTA) recently announced the availability of an AUD $1 million (USD $694,000) drug development research award following the Company's acquisition of Alpha-5... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.